Ocugen announced positive 12-month Phase 2 trial results for OCU410, a gene therapy targeting geographic atrophy (GA) caused by dry age-related macular degeneration (dAMD). The therapy showed a statistically significant 31% reduction in lesion growth compared to control, with no serious adverse events reported. This treatment could offer a one-time alternative to current therapies requiring frequent injections, addressing a major unmet need for millions affected by GA globally. Ocugen plans to start a Phase 3 trial in Q3 2026 to confirm these findings.
Sodexo has secured a major global contract to provide catering services across more than 130 Meta sites in over 30 countries. This large-scale partnership includes diverse locations such as headquarters, campuses, data centers, and conference centers...
Kenmare Resources reported weaker-than-expected production in the first half of 2026 due to commissioning delays at its Wet Concentrator Plant A, with ilmenite output down 40% year on year in Q2. Despite this, shipments increased by 53% as the compan...
Alphamin Resources delivers strong free cash flow from its high-grade Bisie tin mine, maintaining consistent output of 20,000 tonnes per annum. Despite operational risks in the Democratic Republic of Congo, the company trades at a significant valuati...
Thor Explorations produced 19,153 ounces of gold in Q2 2026 from its Segilola mine in Nigeria, maintaining its full-year production guidance of 75,000 to 85,000 ounces. The company generated $77.3 million in revenue by selling 17,050 ounces at an ave...
Angelini Pharma has finalized its $4.1 billion acquisition of Catalyst Pharmaceuticals, enhancing its footprint in the U.S. market and strengthening its global leadership in brain health and rare diseases. The deal includes significant investments fr...
